OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost bought 125,000 shares of the company's stock in a transaction on Tuesday, April 8th. The shares were acquired at an average cost of $1.48 per share, for a total transaction of $185,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 213,876,448 shares of the company's stock, valued at $316,537,143.04. This trade represents a 0.06 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Tuesday, April 1st, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.65 per share, for a total transaction of $165,000.00.
- On Friday, March 28th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.70 per share, with a total value of $255,000.00.
- On Monday, March 17th, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.74 per share, with a total value of $348,000.00.
- On Friday, February 28th, Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock. The stock was acquired at an average cost of $1.71 per share, with a total value of $115,312.14.
- On Tuesday, January 28th, Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock. The stock was bought at an average price of $1.47 per share, with a total value of $69,879.39.
- On Friday, January 17th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.47 per share, with a total value of $220,500.00.
- On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.48 per share, for a total transaction of $740,000.00.
OPKO Health Stock Performance
Shares of NASDAQ OPK opened at $1.46 on Wednesday. The business's 50-day simple moving average is $1.69 and its 200-day simple moving average is $1.58. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a 52 week low of $1.15 and a 52 week high of $2.04. The firm has a market cap of $980.46 million, a price-to-earnings ratio of -7.68 and a beta of 1.78.
OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. As a group, equities research analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on OPK. Barrington Research reaffirmed an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th. HC Wainwright restated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a report on Monday. Finally, StockNews.com upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd.
Get Our Latest Stock Analysis on OPK
Institutional Trading of OPKO Health
Several institutional investors have recently modified their holdings of OPK. Millennium Management LLC boosted its stake in OPKO Health by 85.3% during the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock worth $6,745,000 after buying an additional 2,112,382 shares in the last quarter. Northern Trust Corp increased its stake in OPKO Health by 4.7% in the fourth quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company's stock valued at $5,436,000 after acquiring an additional 164,847 shares during the period. Lazard Asset Management LLC increased its stake in OPKO Health by 143.6% in the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company's stock valued at $3,746,000 after acquiring an additional 1,502,342 shares during the period. Two Sigma Investments LP boosted its holdings in OPKO Health by 136.1% during the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock valued at $2,422,000 after purchasing an additional 949,671 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its position in shares of OPKO Health by 42.3% during the 4th quarter. Nuveen Asset Management LLC now owns 1,432,404 shares of the biotechnology company's stock worth $2,106,000 after buying an additional 425,484 shares during the period. Institutional investors and hedge funds own 64.63% of the company's stock.
About OPKO Health
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
